Amendments to the Specification:

Please replace the paragraph starting at page 20, line 20 and ending at page 21, line 22 with the following amended paragraph:

Figure 4 shows: Figure 4A – the sequence of a ribozyme designed to target a 15 base pair substrate sequence within the luciferase gene (SEQ ID NO: 5), and the substrate sequence (from 716-731 of the luc gene of pGL3-basic) (SEQ ID NO: 4); Figure 4B – the sequence of two complementary oligonucleotides, [[( ]] lucRa (SEQ ID NO: 6) and lucRb (SEQ ID NO: 7) [[ )]]. The reannealed oligos were cloned into SalI/SmaI sites of the expression vector pCI. Figure 4C – a schematic representation of constructs pCI-luc-ribo(9) (left-hand side of the figure), comprising the ribozyme under the control of a CMV promoter and including an intron sequence, and pCI-luc-ribo*(2) (right-hand side of the figure), which is an intron-deleted derivative of the former construct, by PstI/KpnI digestion followed by self-ligation/transfection into bacteria; Table 3 shows results of transfection assays with the constructs: 1 μg Hsp70-luc, in which the luciferase gene is under the control of human Hsp70 promoter (from -117 to +26), or was co-transfected with 1 or 2 μg pCI (lanes 1 and 4), 1 or 2 μg pCI-luc-ribo(9) (lanes 2 and 5, and 1 or 2 μg pCI-luc-ribo*(2) (lanes 3 and 6). The luciferase activity was measured after two days' culture. The effect of the ribozyme over the expression of luciferase is presented as the ratio of the luciferase activity of each transfectant over the transfectants with pCI DNA (column headed "ratio"). This ratio is also shown in plot form in Figure 4D. Background references for ribozyme include Kashani-Sabet and Scanlon, 1995 *Cancer Gene Therapy*, 2(3):213-223, and Mercola and Cohen, 1995, *Cancer Gene Therapy*, 2(1), 47-59.

Please insert the substitute "Sequence Listing" submitted concurrently herewith into the specification in accordance with 37 CFR 1.821 through 1.825.